StreetInsider.com News Articles

Jones Trading Downgrades EyePoint Inc. (EYPT) to Hold

Fri, 23 Oct 2026 16:08:22 -0400

Jones Trading analyst Debanjana Chatterjee downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Hold.

For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.

Shares of EyePoint Inc. closed at $0.43 yesterday.

Laidlaw Downgrades EyePoint Inc. (EYPT) to Hold

Tue, 20 Oct 2026 08:44:34 -0400

Laidlaw analyst Yale Jen downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Hold.

For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.

Shares of EyePoint Inc. closed at $0.44 yesterday.

EyePoint Inc. (EYPT) PT Lowered to $1 at RBC Capital

Tue, 20 Oct 2026 05:50:09 -0400

RBC Capital analyst Lisa Walter lowered the price target on EyePoint Inc. (NASDAQ: EYPT) to $1.00 (from $5.00) while maintaining a Sector Perform rating.

The analyst comments "We caught up with EYPT's CEO, CMO, and head of IR. The LUCIA miss was not well received by investors, with shares -85% at market close. Mgmt. was clear there is still work to do to assess why Duravyu was not able to meet the primary endpoint of non-inferiority in either pivotal study, despite showing evidence of managing disease activity. EYPT is still considering options for wAMD including the possibility of running an additional

EyePoint Inc. (EYPT) PT Lowered to $1 at RBC Capital

Tue, 20 Oct 2026 05:50:09 -0400

RBC Capital analyst Lisa Walter lowered the price target on EyePoint Inc. (NASDAQ: EYPT) to $1.00 (from $5.00) while maintaining a Sector Perform rating.

Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'

Tue, 20 Oct 2026 05:32:04 -0400

(Updated - October 20, 2026 5:32 AM EDT)

Mizuho analyst Graig Suvannavejh downgraded EyePoint Inc. (NASDAQ: EYPT) from Outperform to Neutral with a price target of $0.50.

The analyst comments "Following the company's announcement of negative P3 LUCIA study results for lead asset Duravyu in wet AMD/wAMD, we downgrade EYPT to Neutral. In removing the wAMD opportunity from our model, and transitioning to an estimated cash/share valuation methodology, our 12-month PT moves to $0.50. With the stock closing yesterday -85% (vs. +2% XBI) — and to below estimated YE26 cash/share levels — the market clearly voiced its lack of confidence in (1)

Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'

Tue, 20 Oct 2026 05:32:04 -0400

(Updated - October 20, 2026 5:32 AM EDT)

Mizuho analyst Graig Suvannavejh downgraded EyePoint Inc. (NASDAQ: EYPT) from Outperform to Neutral with a price target of $0.50.

Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'

Tue, 20 Oct 2026 05:32:04 -0400

(Updated - October 20, 2026 5:32 AM EDT)

Mizuho analyst Graig Suvannavejh downgraded EyePoint Inc. (NASDAQ: EYPT) from Outperform to Neutral with a price target of $0.50.

Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'

Tue, 20 Oct 2026 05:32:04 -0400

(Updated - October 20, 2026 5:32 AM EDT)

Mizuho analyst Graig Suvannavejh downgraded EyePoint Inc. (NASDAQ: EYPT) from Outperform to Neutral with a price target of $0.50.

JPMorgan Downgrades EyePoint Inc. (EYPT) to Underweight

Tue, 20 Oct 2026 03:33:00 -0400

JPMorgan analyst Tessa Romero downgraded EyePoint Inc. (NASDAQ: EYPT) from Neutral to Underweight.

The analyst comments: “All in all, given that the first phase 3 trial (LUGANO) evaluating Duravyu in wet AMD failed to achieve the primary endpoint of statistical non-inferiority in mean change in BCVA vs on-label 2mg aflibercept control (see our prior note here), we are not entirely surprised by this morning’s outcome, with the second phase 3 trial (LUCIA) in the same indication similarly failing to achieve the primary endpoint. As such, we see shares remaining under pressure in the medium term. Looking ahead, EyePoint has deprioritized development

JPMorgan Downgrades EyePoint Inc. (EYPT) to Underweight

Tue, 20 Oct 2026 03:33:00 -0400

JPMorgan analyst Tessa Romero downgraded EyePoint Inc. (NASDAQ: EYPT) from Neutral to Underweight.

Guggenheim Downgrades EyePoint Inc. (EYPT) to Neutral

Mon, 19 Oct 2026 12:50:32 -0400

Guggenheim analyst Yatin Suneja downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Neutral.

For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.

Shares of EyePoint Inc. closed at $2.99 yesterday.

Jefferies Downgrades EyePoint Inc. (EYPT) to Hold

Mon, 19 Oct 2026 10:00:30 -0400

(Updated - October 19, 2026 10:00 AM EDT)

Jefferies analyst Kambiz Yazdi downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Hold with a price target of $1.00 (from $8.00).

The analyst commented: "Ph3 LUCIA study of Duravyu (TKI) in wAMD missed primary ep of BCVA non inferiority to aflibercept. This follows the first Ph3 LUGANO missing its ep. Per EYPT, no study irregularities impacted the results, and there aren't meaningful subgroup differences. Co will analyze results further, but path fwd in wAMD seems unlikely. Ph3 DME program fully enrolled w/ data 4Q27. We move to HOLD given limited cash runway + time

Jefferies Downgrades EyePoint Inc. (EYPT) to Hold

Mon, 19 Oct 2026 10:00:30 -0400

(Updated - October 19, 2026 10:00 AM EDT)

Jefferies analyst Kambiz Yazdi downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Hold with a price target of $1.00 (from $8.00).

Jefferies Downgrades EyePoint Inc. (EYPT) to Hold

Mon, 19 Oct 2026 10:00:30 -0400

(Updated - October 19, 2026 10:00 AM EDT)

Jefferies analyst Kambiz Yazdi downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Hold with a price target of $1.00 (from $8.00).

EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut

Mon, 19 Oct 2026 09:38:17 -0400

Investing.com -- EyePoint Inc (NASDAQ:EYPT) shares plummeted 82% in premarket trading on Monday following news that its lead drug candidate, DURAVYU, failed to meet the primary endpoint in a pivotal Phase 3 study for wet age-related macular degeneration. The clinical setback prompted the company to immediately initiate a sweeping corporate restructuring that includes cutting more than half of its workforce.

In the 475-patient LUCIA trial, DURAVYU failed to demonstrate statistical non-inferiority in mean change in best corrected visual acuity compared to the standard-of-care aflibercept control arm. The disappointment mirrors results from the sister LUGANO study, effectively

EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut

Mon, 19 Oct 2026 09:38:17 -0400

Form 8-K EyePoint, Inc. For: Oct 17

Mon, 19 Oct 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20261019/27201827.html

EyePoint cuts 53% of workforce after wet AMD trial failure

Mon, 19 Oct 2026 07:16:50 -0400

EyePoint, Inc. (Nasdaq: EYPT) announced a workforce reduction of approximately 53% and an early conclusion of its pivotal Phase 3 wet age-related macular degeneration (AMD) trials after its DURAVYU drug candidate failed to meet the primary endpoint in the Phase 3 LUCIA study.

The LUCIA trial, evaluating DURAVYU in wet AMD, did not meet its primary endpoint of non-inferiority, though the company said the study showed vision improvements and met secondary endpoints including reduction in treatment burden and anatomic control.

The Watertown, Massachusetts-based company said its board approved the restructuring plan to preserve capital and shift focus to its Phase 3 program

EyePoint cuts 53% of workforce after wet AMD trial failure

Mon, 19 Oct 2026 07:16:50 -0400

The Watertown, Massachusetts-based company said its board approved the restructuring plan to preserve capital and shift focus to its Phase 3 program

EyePoint Announces Strategic Prioritization

Mon, 19 Oct 2026 07:15:00 -0400

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for DURAVYU™ in diabetic macular edema (DME). This strategic realignment follows today’s topline readout from the Phase 3 LUCIA study of DURAVYU in wet AMD, which did not meet its primary endpoint of non-inferiority, despite vision improvements, and despite meeting key secondary endpoints including reduction in treatment burden, supplement-free

EyePoint Announces Strategic Prioritization

Mon, 19 Oct 2026 07:15:00 -0400

Form 8-K EyePoint, Inc. For: Oct 19

Mon, 19 Oct 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20261019/27200552.html

EyePoint's Duravyu fails primary endpoint in second wet AMD trial

Mon, 19 Oct 2026 07:00:38 -0400

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its investigational treatment DURAVYU (vorolanib intravitreal insert) failed to meet the primary endpoint in LUCIA, the second of two pivotal Phase 3 clinical trials evaluating the drug for wet age-related macular degeneration (wet AMD).

LUCIA did not achieve statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to on-label aflibercept 2 mg control, despite patients in the DURAVYU arm showing visual improvement. The trial enrolled 475 patients, who were randomized 1:1 to receive DURAVYU 2.7 mg every 24 weeks or aflibercept every eight weeks.

Key secondary endpoints were met, including a 38% reduction

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

Mon, 19 Oct 2026 07:00:00 -0400

– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –

– Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control –

– Continued favorable safety profile for DURAVYU with redosing –

─ DME program remains on track with pivotal Phase 3 topline data from two identical clinical

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

Mon, 19 Oct 2026 07:00:00 -0400

– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –

– Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control –

– Continued favorable safety profile for DURAVYU with redosing –

─ DME program remains on track with pivotal Phase 3 topline data from two identical clinical